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Abstract We studied the neuroprotective e¡ects of valproic
acid (VPA), a primary mood stabilizer and anticonvulsant, in
cultured rat cerebral cortical neurons (CCNs). CCNs underwent
spontaneous cell death when their age increased in culture. As
shown by mitochondrial activity and calcein-AM assays, treat-
ment of CCNs with VPA starting from day 9 in vitro markedly
increased viability and prolonged the life span of the cultures.
The neuroprotective action of VPA was time-dependent and
occurred at therapeutic levels with a maximal e¡ect at about
0.5 mM. LiCl (1 mM) also protected CCNs from aging-in-
duced, spontaneous cell death but less e¡ectively. VPA-induced
neuroprotection in aging CCN cultures was associated with a
robust increase in histone H3 acetylation levels and the protec-
tive e¡ect was mimicked by treatment with a histone deacetyl-
ase inhibitor, trichostatin A, but not by VPA analogs which are
inactive in blocking histone deacetylase. Our results suggest a
role of histone deacetylase inhibition in mediating the neuro-
protective action of VPA.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Valproic acid (VPA), a short-chained fatty acid, is widely
used for the treatment of seizures. The mechanism(s) under-
lying its anticonvulsant activity is not well understood, but
could be related to its ability to increase the level of Q-amino-
butyric acid (GABA), an inhibitory neurotransmitter, and to
enhance the sensitivity of GABA receptors in the brain (for
review, [1]). Chronic treatment with VPA was also found to be
bene¢cial for patients with bipolar mood disorder [1,2]. VPA
is one of the primary drugs used in the treatment and pro-
phylaxis for both manic and depressive phases of this mood
disorder. Despite intensive research, the mechanisms under-
lying the therapeutic e¡ects of VPA remain obscure. Since
clinical e⁄cacy for VPA requires chronic treatment, it has
been postulated that drug-induced changes in gene expression
are required for its therapeutic actions [3]. Recently, VPA was
reported to directly inhibit histone deacetylase (HDAC) at
therapeutic levels (with an IC50 = 0.4 mM), causing histone
hyperacetylation [4,5]. HDAC has been strongly implicated
in the modulation of gene expression as well as life span in
a variety of organisms such as yeast, Caenorhabditis elegans
and Drosophila [6]. In addition, VPA has been shown to acti-
vate the cell survival factor, Akt, presumably through inhi-
bition of HDAC ([7], E. Chalecka-Franaszek and D.-M.
Chuang, unpublished observations).
Recently, we found that lithium is neuroprotective against a
variety of insults including excitotoxicity in cultured central
nervous system neurons as well as animal models of diseases
(for review, [8]). Our preliminary data also indicate that VPA
protects mature cerebellar granule cells in cultures from glu-
tamate-induced, N-methyl-D-aspartate (NMDA) receptor-
mediated excitotoxicity, but is severely toxic to immature cer-
ebellar granule cells (H. Kanai and D.-M. Chuang, unpub-
lished observations). In this study, we used rat primary neuro-
nal cultures prepared from embryonic cortex, a brain region
where neuroanatomical abnormality has been implicated in
the pathogenesis of bipolar mood disorder [9]. The goals of
the present study were: (1) to investigate whether VPA has
neuroprotective e¡ects in cultured cortical neurons (CCNs)
undergoing spontaneous cell death and (2) to characterize
this VPA-induced neuroprotection and examine whether inhi-
bition of HDAC is involved.
2. Materials and methods
2.1. Animals
All procedures employing experimental rats were performed in
compliance with the National Institutes of Health guidelines for the
care and use of laboratory animals.
2.2. Primary cultures of rat CCNs and drug treatments
CCNs were prepared from 17-day-old embryonic rats and cultured
as described previously [10]. In brief, the cortical tissues were collected
from embryonic rat brain and meninges were removed under sterile
conditions. The cells were dissociated by trypsinization and tritura-
tion, followed by DNase treatment. The cells were resuspended in
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neuron-de¢ned, serum-free Neurobasal medium (Gibco BRL, Grand
Island, NY, USA), supplemented with B-27, glutamine (500 WM) and
glutamate (25 WM). The cells were plated at a density of 4.2U105
cells/cm2 on polyethyleneimine-coated 96-well or 6-well plates. Cul-
tures were then kept in a humidi¢ed atmosphere of 95% air and 5%
CO2 at 37‡C. Over 95% of the cells present on day 5 in vitro were
di¡erentiated into neurons, as characterized by the appearance of long
neurites expressing neuro¢lament protein. On day 9 in vitro, cultures
were treated with 0.1^1 mM VPA and maintained until the measure-
ments.
2.3. Measurement of cell viability
Cortical neuronal cultures were plated on 96-well plates and main-
tained for 23 days. Viability of cortical neurons was determined by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay, which detects mitochondrial dehydrogenase activity [10]. Cell
viability was expressed as a percentage of the value in untreated con-
trol culture. One-way ANOVA was used for statistical analysis, and
signi¢cant di¡erences in cell viability were determined by post hoc
comparisons of means using the Bonferroni test. In some experiments,
cell viability was also assessed in CCNs grown in 6-well plates using
the membrane-permeable dye calcein-AM, which is hydrolyzed by an
intracellular esterase in viable cells to yield a green £uorescent prod-
uct. Cells were washed three times with phosphate-bu¡ered saline
(PBS) and then incubated with 2 WM calcein-AM for 10 min at
37‡C before microscopic examination for green £uorescence.
2.4. Nuclear staining of DNA
For microscopic nuclear DNA analysis, cortical neuronal cultures
were plated on 12-mm glass coverslips and maintained for 23 days.
Cultures were washed with PBS and ¢xed with 4% formaldehyde in
PBS for 10 min at 4‡C. After ¢xation, cells were washed three times
with PBS and then stained with 5 Wg/ml Hoechst dye 33258 for 5 min
at 4‡C to detect chromatin condensation. Stained cells were washed
again with PBS. Cells were visualized under UV illumination (400U)
using a Zeiss Axiophot microscope.
2.5. Western blotting
All procedures of Western blotting analysis of protein have been
described elsewhere [10]. Brie£y, cells were lysed with sodium dodecyl
sulfate (SDS) bu¡er (50 mM Tris^HCl, pH 7.5, 0.5% SDS, 1 mM
dithiothreitol) and the lysates were sonicated and protein concentra-
tions were determined by the BCA kit (Pierce, New York, NY, USA)
using bovine serum albumin as the standard. Aliquots of 50 Wg pro-
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Fig. 1. VPA promotes cell survival in aging cortical neuronal cultures. A: VPA-induced neuroprotection revealed by £uorescent microscopy.
CCN cultures were treated with 0.5 mM VPA or its vehicle for 14 days starting after day 9 in vitro. Viable cells were stained with calcein-AM
yielding green £uorescence. Bar: 30 Wm. B: VPA inhibits aging-induced chromatin condensations. CCN cultures were treated with 0.5 mM
VPA from day 9 in vitro for 14 days then treated with Hoechst 33258 for nuclear DNA staining. Photographs of cell nuclei are from a typical
experiment of three independent repeats with similar results. Arrows show nuclear fragmentation and arrowheads show nuclear chromatin con-
densation. Bar: 10 Wm. C: Life span extension by VPA. Cortical neurons were treated with 0.5 mM VPA from day 9 in vitro and viable cells
stained with calcein-AM were counted at various times thereafter. Data are the meansSS.E.M. of the percent of viable cell number on day 9
in vitro in the control culture and are derived from three independent experiments. ***P6 0.001 compared with respective control. D,E: Time-
and dose-dependent neuroprotection by VPA. CCN cultures were exposed to 0.5 mM VPA for various times (0^14 days) (D) or to indicated
concentrations of VPA for 14 days (E). All neuronal viabilities were determined on day 23 in vitro using the MTT assay. Data are the means
SS.E.M. of the percent of vehicle control from ¢ve independent experiments. *P6 0.05, ***P6 0.001 compared with control.
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tein were subjected to SDS^polyacrylamide gel electrophoresis. Sepa-
rated proteins were transferred onto a polyvinylidene di£uoride mem-
brane, which was incubated with a primary polyclonal antibody
against acetyl histone H3 (Upstate, Lake Placid, NY, USA). Mem-
branes were washed and then exposed to the secondary antibody.
Immunoreactive protein bands were visualized by using horseradish
peroxidase-conjugated anti-rabbit IgG and ECL detection reagent
(Amersham Biosciences, Piscataway, NJ, USA). Protein intensities
were quanti¢ed using a CCD camera (Sierra Scienti¢c, Sunnyvale,
CA, USA) and Macintosh NIH Image 1.62 software. Data were eval-
uated for signi¢cance by one-way ANOVA and Student’s t-test.
3. Results
3.1. Protective e¡ects of VPA on aging-induced spontaneous
neuronal cell death
CCNs underwent spontaneous cell death as their age in-
creased in culture. Treatment of CCNs with 0.5 mM VPA
starting from day 9 in vitro markedly suppressed spontaneous
cell death assessed by viable cell staining with calcein-AM
within a time frame of 23 days after plating (Fig. 1A). The
aging cultures showed extensive chromatin condensation and
nuclear fragmentation, a hallmark of apoptosis (Fig. 1B). The
occurrence of these apoptotic markers was also inhibited by
VPA treatment. The life span of CCNs was approximately
90 days in VPA-treated cultures, compare with about 70
days in saline-treated controls (Fig. 1C). The number of viable
neurons was increased to 140%, 166% and 210% of the re-
spective control values after VPA treatment for 1, 2, and
3 weeks, respectively. The neuroprotective e¡ect of VPA was
time-dependent with a progressive increase in the extent of
neuroprotection between 1 day and 14 days of treatment
(Fig. 1D). The VPA neuroprotection was evident in the con-
centration range of 0.1^1.0 mM following treatment for
14 days with maximal protection at 0.5^0.75 mM (Fig. 1E).
3.2. Drug selectivity for neuroprotection in cortical neuronal
cultures
Other drugs were examined for their neuroprotective e¡ects
in the CCN cultures. The mood stabilizer lithium protected
CCNs from spontaneous cell death but less robustly (Fig.
2A). Another mood stabilizer, carbamazepine (10^100 WM),
neuroleptics such as haloperidol (1^100 nM) and risperidone
(10^300 nM) as well as antidepressants such as desipramine
(0.1^3 WM) and £uoxetine (0.1^3 WM) did not have signi¢cant
e¡ects (Fig. 2B,C).
3.3. Role of HDAC inhibition in VPA-induced neuroprotection
The neuroprotective e¡ect of VPA in the aging CCN cul-
tures was associated with a marked hyperacetylation of his-
tone H3. Following treatment for 14 days with VPA (0.5 mM)
or trichostatin A (TSA) (30 nM), a HDAC inhibitor, the
levels of acetylated histone H3 were increased by more than
two-fold (Fig. 3A), suggesting the occurrence of HDAC inhi-
bition. The VPA-induced elevation of histone H3 acetylation
was time-dependent with a signi¢cant increase after treatment
for 1^7 days, and an even more robust elevation after 2 weeks
of treatment (Fig. 3B). Exposure of CCN cultures to up to
30 nM TSA for 14 days also induced a concentration-depen-
dent neuroprotection; further increase of concentration re-
sulted in reversal of the protective e¡ect (Fig. 4A). In contrast,
treatment with valpromide and 2-methyl-2-pentenoic acid
(2M2P), two structural analogs of VPA devoid of HDAC
inhibitory activity [4], were without e¡ect on neuronal viabil-
ity in the examined concentration range of 0.1^1 mM (Fig.
4B). The spontaneous cell death in CCN cultures was also
una¡ected by the presence (from 9 to 23 days in vitro) of
inositol (1^10 mM), glucose (1^10 mM), an inhibitor of cas-
pase-3 (DEVD-fmk; 10^100 WM), antagonists of NMDA re-
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Fig. 2. Selectivity of drug-induced neuroprotection in cortical neuronal cultures. CCN cultures on day 9 in vitro were treated with indicated
concentrations of mood stabilizers (A), neuroleptics (B), or antidepressants (C). Cell viability was determined on day 23 in vitro using the
MTT assay. Data are the meansSS.E.M. of the percent of vehicle control from three independent experiments. **P6 0.01 compared with con-
trol.
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ceptors (MK-801; 10^50 WM) and non-NMDA receptors
(CNQX and DNQX; 10^50 WM) as well as propyl oligopep-
tidase inhibitor-1 (POI-1; 1^100 WM) (data not shown).
4. Discussion
The present study shows that VPA markedly prolonged the
life span of CCNs when added to maturing cultures. The
neuroprotective e¡ect was concentration-dependent with a
maximal e¡ect occurring at 0.5^1.0 mM which is within the
therapeutic dose range of this drug used for the treatment of
manic-depressive illness and seizure. The selectivity of the
protection was examined using other mood stabilizers. Lith-
ium was also neuroprotective against spontaneous cell death
but less robustly, while carbamazepine was ine¡ective. More-
over, the neuroleptic haloperidol and clinical antidepressants
were unable to protect these neurons from cell death, thus
indicating the selectivity of the neuroprotection. In the case
of cerebellar granule cells in cultures, the spontaneous, aging-
induced apoptotic death is robustly suppressed by NMDA
receptor antagonist [11]. However, the death of CCNs was
una¡ected by antagonists of NMDA and non-NMDA recep-
tors, suggesting that it is not due to excitotoxicity induced by
glutamate excessively released into the medium. Although the
aging culture of CCN is characterized by the appearance of
the apoptotic marker chromatin condensation, the culture was
not protected by a caspase-3 inhibitor, implying that other
form(s) of caspases are involved. It has been recently reported
that VPA and lithium inhibit the collapse of growth cones and
increase the growth cone area in sensory neurons [12]. More-
over, these VPA and lithium e¡ects are blocked by supple-
Fig. 3. E¡ects of VPA and TSA on levels of histone H3 acetylation
in cortical neuronal cultures. A: VPA and TSA increase levels of
acetylation of histone H3. CCN cultures after 9 days in vitro were
treated with 0.5 mM VPA or 30 nM TSA for 14 days and then har-
vested for Western blotting for levels of acetylated histone H3.
Upper panels: acetylated histone H3 immunoblots in duplicate.
Lower panel: quanti¢ed relative immunoreactivity of acetylated his-
tone H3 protein bands expressed as meansSS.E.M. of the percent
of vehicle control averaged from three independent experiments.
B: VPA-induced increase of acetylated histone H3 levels is time-de-
pendent. Cortical cultures were treated with 0.5 mM VPA or its ve-
hicle for the indicated times. All cultures were harvested on day 23
in vitro for Western blotting. Upper panel: acetylated histone H3
immunoblot. Lower panel: quanti¢ed relative immunoreactivity of
acetylated histone H3 protein band expressed as meansSS.E.M. of
the percent of untreated control averaged from three independent
experiments. **P6 0.01, ***P6 0.001 compared with control.
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Fig. 4. TSA, but not valpromide or 2M2P, increases viability of cor-
tical neurons in aging cultures. A: TSA-induced neuroprotection.
CCN cultures were treated with indicated concentrations of TSA
for 14 days. Cell viability was determined on day 23 in vitro using
MTT assay. Data are the meansSS.E.M. of the percent of vehicle
control from three independent experiments. **P6 0.01,
***P6 0.001 compared with control. B: Lack of e¡ect of valpro-
mide and 2M2P on cell viability. CCN cultures were treated with
indicated concentrations of valpromide or 2M2P for 14 days. Cell
viability was determined on day 23 in vitro using the MTT assay.
Data are the meansSS.E.M. of the percent of vehicle control from
three independent experiments.
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mentation with inositol or addition of propyl oligopeptidase
inhibitors. However, in the present study, we found that ino-
sitol and POI-1 a¡ected neither the spontaneous cell death nor
the neuroprotective action of VPA. Thus, inositol depletion
and propyl oligopeptidase activity do not seem to participate
in neuroprotection by VPA. VPA appears to have subtle ef-
fects of increasing the length and number of neurites of CCNs
after 2 weeks of treatment (Fig. 1A). These e¡ects could be
related to the observations by Hall et al. [13] that VPA in-
duces axonal remodeling and synapsin clustering in develop-
ing neurons. It has been suggested that these e¡ects are due to
indirect inhibition by VPA of the activity of glycogen synthase
kinase-3 (GSK-3) [13]. The role of GSK-3 in mediating the
neuroprotective e¡ects of VPA in CCNs requires further stud-
ies.
VPA-induced neuroprotection was concentration- and time-
dependently associated with an increased level of histone H3
acetylation, thus consistent with the ability of this drug to
inhibit HDAC [4,5] and the role of this action in prolonging
the life span of our neuronal cultures. This notion is further
supported by our observation that TSA, a prominent HDAC
inhibitor, mimics the neuroprotective e¡ect of VPA on corti-
cal neurons. Additionally, valpromide and 2M2P, which are
structurally related to VPA but unable to inhibit HDAC [4],
were ine¡ective in protecting CCNs. It should be noted that
both valpromide and 2M2P are anticonvulsants with no ter-
atogenic e¡ects, dissimilar to VPA [14]. Based on these obser-
vations, it has been suggested that HDAC inhibition is related
to the teratogenic e¡ect of VPA [4,5]. Our results provide the
novel information that HDAC inhibition can contribute to
the neuroprotective e¡ect of VPA.
HDACs such as RPD3 and SIR2 are known to be involved
in the regulation of life span of yeast and the nematode
C. elegans [15,16]. A HDAC inhibitor, phenylbutyrate, also
signi¢cantly increases the life span of Drosophila [6]. It has
been suggested that induction and/or repression of genes in-
volved in longevity through HDAC inhibition is a determin-
ing factor for increasing the life span in those organisms [6].
Some of the prominent genes markedly induced by phenyl-
butyrate in Drosophila are superoxide dismutase which has a
central role in antioxidation and detoxi¢cation, and the cyto-
protective heat shock response proteins [6]. Our preliminary
results showed that the expression of superoxide dismutase
was una¡ected by VPA exposure for 2 weeks in cortical neu-
rons, but heat shock protein 70 appeared to be signi¢cantly
up-regulated. Interestingly, HDAC inhibition results in down-
regulation of glyceraldehyde-3-phosphate dehydrogenase [6].
We have reported that this so-called housekeeping gene is in
fact up-regulated and plays a prominent role in aging-induced
apoptosis of cultured cerebellar granule cells [17]. Future stud-
ies will be necessary to identify precise VPA-targeted gene(s)
involved in the neuroprotection of CCN cultures. In this con-
text, VPA has been reported to induce anti-apoptotic proteins
such as Bcl-2 and GRP-78 (78-kDa glucose-regulated protein)
[18,19]. It remains to be investigated whether these genes are
under the regulation of histone deacetylation and if they have
a major role in VPA-elicited neuroprotection in cortical neu-
ronal cultures.
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